Ignite Creation Date:
2024-05-06 @ 4:33 PM
Last Modification Date:
2024-10-26 @ 2:12 PM
Study NCT ID:
NCT05022043
Status:
COMPLETED
Last Update Posted:
2021-08-26
First Post:
2021-08-21
Brief Title:
Serum Presepsin as Early Predictor for Neonatal Early-onset Sepsis
Sponsor:
Tanta University
Organization:
Tanta University
Study Overview
Official Title:
At Admission Serum Presepsin as Early Predictor for Disease Severity and Positive Blood Culture for Neonates With Early-onset Sepsis
Status:
COMPLETED
Status Verified Date:
2021-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
124 neonates aged 7 days with suspected EOS were clinically evaluated using SNAP-II and gave blood samples for BC total leucocytic count TLC lymphocytic and neutrophil count and ELISA estimation of serum levels of PSP procalcitonin PCT and tumor necrosis factor-α TNF-α Enrolled neonates were categorized as Confirmed EOS neonates with evident clinical sepsis manifestations and positive BC Suspected EOS neonates with evident clinical sepsis manifestations but had negative BC and No EOS included neonates free of evident clinical sepsis manifestations had negative BC and showed no deterioration till 72-hr after admission
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None